Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report.
This study reports a case of bevacizumab administered to treat choroidal neovascularisation in a woman later discovered to be pregnant. A 25-year-old pregnant woman developed myopic choroidal neovascularisation in both eyes. Both eyes were treated with a total of 3 intravitreal injections of bevacizumab sequentially. Vision improved significantly in both eyes. There were no evident pregnancy-related complications at 1 year postpartum. Although anti-vascular endothelial growth factor (VEGF) therapy did not result in any detectable short-term adverse event in this mother and baby, the potential toxicity of these agents must be carefully considered in pregnant patients.